Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $502,793 - $572,886
3,146 Added 33.95%
12,413 $2.26 Million
Q4 2023

Feb 12, 2024

BUY
$137.6 - $154.97 $288,684 - $325,127
2,098 Added 29.26%
9,267 $1.44 Million
Q3 2023

Oct 31, 2023

BUY
$133.59 - $154.65 $84,562 - $97,893
633 Added 9.68%
7,169 $1.07 Million
Q2 2023

Aug 04, 2023

BUY
$132.51 - $164.9 $143,375 - $178,421
1,082 Added 19.84%
6,536 $880,000
Q1 2023

Apr 25, 2023

BUY
$144.61 - $166.54 $447,857 - $515,774
3,097 Added 131.4%
5,454 $869,000
Q4 2022

Aug 27, 2024

BUY
$138.31 - $165.87 $1.06 Million - $1.27 Million
7,634 New
7,634 $1.23 Billion
Q4 2022

Feb 03, 2023

SELL
$138.31 - $165.87 $1.34 Million - $1.6 Million
-9,675 Reduced 80.41%
2,357 $381,000
Q3 2022

Aug 26, 2024

BUY
$134.21 - $153.93 $92,604 - $106,211
690 Added 6.25%
11,731 $1.57 Billion
Q3 2022

Oct 17, 2022

BUY
$134.21 - $153.93 $73,144 - $83,891
545 Added 4.74%
12,032 $1.62 Million
Q2 2022

Aug 26, 2024

BUY
$137.62 - $174.96 $1.52 Million - $1.93 Million
11,041 New
11,041 $1.69 Billion
Q2 2022

Jul 20, 2022

BUY
$137.62 - $174.96 $70,599 - $89,754
513 Added 4.67%
11,487 $1.76 Million
Q1 2022

Aug 26, 2024

BUY
$131.98 - $163.75 $1.4 Million - $1.74 Million
10,638 New
10,638 $1.72 Billion
Q1 2022

Jul 19, 2022

SELL
$131.98 - $163.75 $5,411 - $6,713
-41 Reduced 0.37%
10,974 $1.78 Million
Q1 2022

Apr 18, 2022

SELL
$131.98 - $163.75 $2.87 Million - $3.56 Million
-21,760 Reduced 66.39%
11,015 $1.79 Million
Q4 2021

Aug 22, 2024

BUY
$107.43 - $135.93 $1.13 Million - $1.43 Million
10,501 New
10,501 $1.42 Billion
Q4 2021

Jan 31, 2022

BUY
$107.43 - $135.93 $3.52 Million - $4.46 Million
32,775 New
32,775 $4.44 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $342B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Peterson Financial Group, Inc. Portfolio

Follow Peterson Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peterson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Peterson Financial Group, Inc. with notifications on news.